KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and ...

Induced pluripotent stem-cell-derived corneal epithelium to treat limbal stem cell deficiency could transform eye care and ...

Dr. Roy Rubinfeld, an internationally renowned corneal surgeon and innovator, has developed a groundbreaking epithelium-on ...

This procedure involves reshaping the cornea, the eye’s clear front surface, to improve how light focuses on the retina.

During this year’s peak ozone depletion season (September 7-October 13), the ozone hole above the Antarctic was ranked the ...

Tear film hyperosmolarity acts as a potent cellular stress on the ocular surface that can induce epithelial cell death and ...

Recommendations emphasize monitoring rapid keratoconus progression in patients under 18.

A recent groundbreaking study revealed that trans-epithelial phototherapeutic keratectomy (TE-PTK) is safe and efficient for ...

HC Wainwright reissued their buy rating on shares of KALA BIO (NASDAQ:KALA – Free Report) in a report released on Friday,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

2024年11月12日，科技日报报道了一项令人瞩目的医学突破。日本大阪大学的科学家首次利用人类诱导多能干细胞（iPS细胞）转化而来的角膜组织，成功修复了4名角膜缘干细胞缺乏症（LSCD）患者的角膜。这一创新性的研究不仅为角膜疾病患者带来了新的希望，也 ...

A year following the transplant, distance visual acuity had improved in all four patients and corneal opacity had diminished ...

Patients with limbal deficiency may benefit from limbal stem cell transplantation to alleviate persistent epithelial defects, maintain conjunctivalization regression and corneal avascularity ...